HeyJaredPuyaan Singh
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 14, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 16, 2026
Latest articles
Experts urge FDA to set clear safety and access standards for psychedelic drugs (opens the original)
Read excerpt
Sept 14 (Reuters) - Doctors, veterans, pharmacists and therapists on Monday urged the U.S. Food and Drug Administration to establish clear safety and access standards for psychedelic therapies during a four-hour public meeting convened by the agency amid efforts to speed up their development. The hearing is the latest in a months-long push launched by U.S. President Donald Trump's administration in April to bring qualified psychedelic drug programs to market. Discussions at the meeting focused o
Acting US FDA Chief Urges Confidence in Lettuce as Agency Updates Produce Safety Guidance (opens the original)
Read excerpt
Aug 11 (Reuters) - Acting U.S. FDA Commissioner Kyle Diamantas said on Tuesday Americans should feel confident in eating fresh produce, as the agency has finalized guidance for proper preparation and packaging amid ongoing foodborne outbreaks. The Food and Drug Administration's updated guidance for producers and suppliers recommends measures such as sanitation control, supplier verification and refrigeration amid the ongoing outbreaks of cyclosporiasis and salmonella linked to fresh produce. T
J&J enters robotic surgery market after device gets marketing authorization (opens the original)
Read excerpt
NEW BRUNSWICK, N.J. — Johnson & Johnson said on Wednesday the Food and Drug Administration had granted marketing authorization for its robotic surgery device, as the healthcare conglomerate enters the soft-tissue robotic surgery market. The decision marks a key step for J&J's medtech business that had been seeking to compete in the robotic-assisted surgery market, currently dominated by Intuitive Surgical's da Vinci system. Medtronic's Hugo robot was also approved last year. J&J's Ottava ro
Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug (opens the original)
Read excerpt
July 16 (Reuters) - The U.S. FDA approved Merck's cholesterol-lowering pill, it said on Thursday, the first in a class of drugs dominated by injections, which could potentially broaden the use of cholesterol medication among people at risk of heart disease. The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes elevated levels of LDL, the so-called "bad" cholesterol in the blood that often lea
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.